Bristol-Myers Squibb (NYSE: BMY) reported Q3 EPS of $2.00, $0.06 better than the analyst estimate of $1.94. Revenue for the quarter came in at $11.62 billion versus the consensus estimate of $11.64 billion.

GUIDANCE:

Bristol-Myers Squibb sees FY2021 EPS of $7.40-$7.55, versus the consensus of $7.47.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.